ECSP21078893A - Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) - Google Patents

Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)

Info

Publication number
ECSP21078893A
ECSP21078893A ECSENADI202178893A ECDI202178893A ECSP21078893A EC SP21078893 A ECSP21078893 A EC SP21078893A EC SENADI202178893 A ECSENADI202178893 A EC SENADI202178893A EC DI202178893 A ECDI202178893 A EC DI202178893A EC SP21078893 A ECSP21078893 A EC SP21078893A
Authority
EC
Ecuador
Prior art keywords
hbv
virus
active against
against hepatitis
compounds
Prior art date
Application number
ECSENADI202178893A
Other languages
English (en)
Inventor
Jasper Springer
Susanne Bonsmann
Burkhard Klenke
Andreas Urban
Alastair Donald
Original Assignee
Aicuris Gmbh Co Kg [De/De]
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh Co Kg [De/De] filed Critical Aicuris Gmbh Co Kg [De/De]
Publication of ECSP21078893A publication Critical patent/ECSP21078893A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere, en general, a nuevos agentes antivíricos. Específicamente, la presente invención se refiere a compuestos que pueden inhibir la proteína o proteínas codificada(s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, a composiciones que comprenden estos compuestos, a métodos para inhibir la replicación del virus VHB, a métodos para tratar o prevenir la infección por VHB y a procesos o intermedios para fabricar los compuestos.
ECSENADI202178893A 2019-04-30 2021-10-25 Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb) ECSP21078893A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19172007 2019-04-30
EP19172401 2019-05-02

Publications (1)

Publication Number Publication Date
ECSP21078893A true ECSP21078893A (es) 2021-11-30

Family

ID=70391140

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202178893A ECSP21078893A (es) 2019-04-30 2021-10-25 Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)

Country Status (19)

Country Link
US (1) US20220227785A1 (es)
EP (1) EP3962912A1 (es)
JP (1) JP2022531199A (es)
KR (1) KR20220002499A (es)
CN (1) CN113767102A (es)
AU (1) AU2020265390A1 (es)
BR (1) BR112021021580A2 (es)
CA (1) CA3138384A1 (es)
CL (1) CL2021002794A1 (es)
CU (1) CU20210089A7 (es)
EC (1) ECSP21078893A (es)
IL (1) IL287240A (es)
MX (1) MX2021013086A (es)
PH (1) PH12021552749A1 (es)
PY (1) PY2018617A (es)
SG (1) SG11202111333UA (es)
TW (1) TW202106685A (es)
UY (1) UY38683A (es)
WO (1) WO2020221816A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3080971A1 (en) 2017-11-02 2019-05-09 Calico Life Sciences Llc Modulators of the integrated stress pathway
US11845752B2 (en) 2020-10-15 2023-12-19 Aligos Therapeutics, Inc. Substituted imidazo[1,5-a]pyrazines for the treatment of hepatitis B

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
WO2000058302A1 (de) 1999-03-25 2000-10-05 Bayer Aktiengesellschaft Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b
DE60033657T2 (de) 1999-04-23 2007-11-08 Extenday IP Ltd., Kumeu Foliebefestigungs- und verankerungsteil
WO2001045712A1 (de) 1999-12-22 2001-06-28 Bayer Aktiengesellschaft Arzneimittelkombinationen gegen virale erkrankungen
CA2568389A1 (en) 2004-06-09 2005-12-22 Merck & Co., Inc. Hiv integrase inhibitors
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
JP5977347B2 (ja) 2011-07-01 2016-08-24 バルーク エス．ブルームバーグ インスティテュート Ｈｂｖ感染に対する抗ウイルス剤としてのスルファモイルベンズアミド誘導体
EA037918B1 (ru) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Противовирусные агенты против гепатита в
AU2013207205B2 (en) 2012-01-06 2017-02-02 Janssen Sciences Ireland Uc 4,4-disubstituted-1,4-dihydropyrimidines and the use thereof as medicaments for the treatment of Hepatitis B
HK1208465A1 (en) 2012-08-28 2016-03-04 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
SG11201501360TA (en) 2012-08-28 2015-03-30 Janssen Sciences Ireland Uc Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
RS57999B1 (sr) 2013-05-17 2019-01-31 Janssen Sciences Ireland Uc Derivati sulfamoiltiofenamida i njihova primena kao lekovi za tretman hepatitisa b
WO2014184328A1 (en) 2013-05-17 2014-11-20 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
ES2774749T3 (es) 2013-07-25 2020-07-22 Janssen Sciences Ireland Unlimited Co Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis B
US10220034B2 (en) 2013-10-18 2019-03-05 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
EA201690979A1 (ru) 2013-11-14 2016-08-31 Новира Терапьютикс, Инк. Производные азепана и способы лечения инфекций гепатита в
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
AU2015226206B2 (en) 2014-03-07 2017-03-16 F. Hoffmann-La Roche Ag Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
MX363600B (es) 2014-03-13 2019-03-28 Univ Indiana Res & Tech Corp Moduladores alostericos de proteina nucleo de hepatitis b.
MY196243A (en) 2014-03-28 2023-03-24 Sunshine Lake Pharma Co Ltd Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
AU2015255656A1 (en) 2014-05-09 2016-11-10 Assembly Biosciences, Inc. Methods and compositions for treating hepatitis B virus infections
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
WO2016089990A1 (en) 2014-12-02 2016-06-09 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for hbv treatment
WO2016109684A2 (en) 2014-12-30 2016-07-07 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis b infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
MA52701A (fr) 2015-03-16 2021-03-31 Hoffmann La Roche Traitement combiné avec un agoniste tlr7 et un inhibiteur d'assemblage de capside du virus de l'hépatite b
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10273228B2 (en) 2015-04-17 2019-04-30 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
WO2017011552A1 (en) 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN107849037B (zh) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TWI721016B (zh) 2015-09-15 2021-03-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
HK1259410A1 (zh) 2015-09-29 2019-11-29 诺维拉治疗公司 乙型肝炎抗病毒剂的晶体形式
WO2017076286A1 (zh) 2015-11-04 2017-05-11 南京明德新药研发股份有限公司 二氢吡啶并环化合物的晶型、制备方法和中间体
US10280175B2 (en) 2016-02-02 2019-05-07 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
BR112018067964B1 (pt) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc Composto, composição farmacêutica que o compreende e uso do referido composto
CN109311865B (zh) 2016-04-06 2021-08-31 上海挚盟医药科技有限公司 抗乙肝病毒的吡唑-噁唑烷酮类化合物
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
MA45550A (fr) * 2016-06-29 2019-05-08 Novira Therapeutics Inc Dérivés de diazépinone et leur utilisation dans le traitement des infections par l'hépatite b
ES2817426T3 (es) * 2016-06-29 2021-04-07 Novira Therapeutics Inc Derivados de oxadiazepinona y su uso en el tratamiento de infecciones por hepatitis B
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JP7034133B2 (ja) 2016-07-14 2022-03-11 エフ．ホフマン－ラ ロシュ アーゲー 感染性疾患の処置のためのカルボキシ ６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物
JP7051804B2 (ja) * 2016-07-14 2022-04-11 エフ．ホフマン－ラ ロシュ アーゲー 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3036245C (en) 2016-09-13 2021-07-20 Arbutus Biopharma Corporation Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
ES2898217T3 (es) 2017-03-02 2022-03-04 Assembly Biosciences Inc Compuestos de sulfamida cíclica y métodos de uso de los mismos
MA49014A (fr) 2017-03-21 2020-02-05 Arbutus Biopharma Corp Dihydroindène-4-carboxamides substitués, leurs analogues et procédés d'utilisation correspondant
US11591334B2 (en) 2017-05-04 2023-02-28 Shanghai Longwood Biopharmaceuticals Co., Ltd. Substituted pyrrolizines for the treatment of hepatitis B
WO2019020070A1 (zh) 2017-07-27 2019-01-31 江苏恒瑞医药股份有限公司 哌嗪并杂芳基类衍生物、其制备方法及其在医药上的应用
TW201912153A (zh) 2017-08-30 2019-04-01 加拿大商愛彼特生物製藥公司 用於治療ｂ型肝炎的化合物、醫藥組合物及方法
US10759774B2 (en) 2017-09-28 2020-09-01 The Curators Of The University Of Missouri Inhibitors of hepatitis B virus targeting capsid assembly
UY38437A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)

Also Published As

Publication number Publication date
CN113767102A (zh) 2021-12-07
PY2018617A (es) 2021-08-02
JP2022531199A (ja) 2022-07-06
CU20210089A7 (es) 2022-06-06
KR20220002499A (ko) 2022-01-06
PH12021552749A1 (en) 2022-07-11
CA3138384A1 (en) 2020-11-05
EP3962912A1 (en) 2022-03-09
CL2021002794A1 (es) 2022-06-17
MX2021013086A (es) 2021-11-17
BR112021021580A2 (pt) 2022-01-04
US20220227785A1 (en) 2022-07-21
TW202106685A (zh) 2021-02-16
WO2020221816A1 (en) 2020-11-05
IL287240A (en) 2021-12-01
SG11202111333UA (en) 2021-11-29
AU2020265390A1 (en) 2021-12-23
UY38683A (es) 2020-11-30

Similar Documents

Publication Publication Date Title
MX2020004838A (es) Nuevas indol-2-carboxamidas sustituidas con pirazolopiperidina, de alta actividad, activas contra el virus de la hepatitis b (vhb).
ECSP20029558A (es) Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb)
ECSP21079317A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
CL2021001117A1 (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
CL2021001116A1 (es) Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
ECSP21078893A (es) Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)
UY38439A (es) Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
ECSP21080338A (es) Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb)
PY2018614A (es) Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb)